# US 8,278,337 B2 · Substituted pyridines that are JNK inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,337 B2
- Document ID: US8278337B2
- Status: Granted
- Kind: B2
- Application number: 12/519,731
- Filed: 2007-12-17
- Published: 2010-07-15
- Granted: 2012-10-02
- Earliest claimed: 2006-12-20
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: David B. Belanger; M. Arshad Siddiqui; Patrick J. Curran; Blake Hamann; Lianyun Zhao; Panduranga Adulla P. Reddy; Praveen K. Tadikonda; Gerald W. Shipps, Jr.; Umar Faruk Mansoor
- Web page: https://patentgrep.com/patent/US8278337B2

## CPC

- C07D 417/12: linked by a chain containing hetero atoms as chain links
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/06: Antiasthmatics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/81: Amides; Imides
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/14: containing three or more hetero rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compounds of the formula (I) wherein X is N or CH, and Y is N or CR5. Also disclosed are methods of treating JNK and ERK mediated diseases using the compounds of formula 1.0.

## Claims

### Claim 1

A compound of the formula:
or pharmaceutically acceptable salts or esters thereof, wherein
X is N;
Y is CR5 wherein R5 is H;
R1A is H;
R2A is H;
R3 is —C(O)NR8R9;
R4 is —C(O)NR6R7;
R6 is H;
R7 is alkyl;
R8 is H;
R9 is selected from the group consisting of:
(1) heteroarylalkyl-, and
(2) substituted heteroarylalkyl wherein said substituted heteroarylalkyl is substituted with 1 to 3 substituents independently selected from the group consisting of:
(a) —NH2,
(b) —NH(C1 to C6)alkyl,
(c) —N((C1 to C6)alkyl)2 wherein each alkyl is independently selected,
(d) alkyl,
(e) halo,
(f) aryl,
(g) substituted aryl wherein said substituted aryl is substituted with 1 to 3 substituents independently selected from the group consisting of: (i) —SO2R20, (ii) —OR21, (iii) -halo, (iv) —CN, (v) —CF3, (vi) aminoalkyl-, (vii) —S(O)R26, and (viii) alkyl,
(h) heterocycloalkyl,
(i) heteroaryl,
(j) substituted aryl substituted with 1 to 3 substituents independently selected from the group consisting of: alkyl, —CF3, F, Cl, and Br,
(k) substituted heteroaryl, substituted with 1 to 3 substituents selected from the group consisting of: (i) alkyl, (ii) halo, (iii) CN, (iv) NH2, (v) —NH(C1-C6 alkyl), (vi) —N(C1-C6 alkyl)2 wherein each alkyl is independently selected, (vii) —CF3, (viii) substituted aryl wherein said substituted aryl is substituted with 1 to 3 substitutents independently selected from the group consisting of: —S(O)2R42 and —CN, and (ix) —C(O)NR44R46,
(l) alkylamino-,
(m) heterocycloalkyl-alkyl-amino-,
(n) alkylaminoalkylamino-,
(o) —NHC(O)OR30, and
(p) —NHC(O)NR32R34;
R20 is selected from the group consisting of: (1) alkyl, (2) dialkylamino (wherein each alkyl is independently selected), (3) —NH2, (4) alkylamino, (5) heterocycloalkyl, and (6) substituted heterocycloalkyl wherein said substituted heterocycloalkyl is substituted with 1 to 2 substitutents independently selected from the group consisting of: —C(O)OR40;
R21 is alkyl;
R26 is alkyl;
R30 is alkyl;
Each R32 and R34 is independently selected from the group consisting of: H, alkyl, aryl, aryl substituted with a —OH group, and heteroaryl;
R40 is alkyl; and
Each R44 and R46 is independently selected from the group consisting of: H and alkyl.

### Claim 2 (depends on 1)

The compound of claim 1 wherein R4 is —C(O)NH(i-propyl).

### Claim 3 (depends on 1)

The compound of claim 1 wherein R9 is heteroarylalkyl.

### Claim 4 (depends on 1)

The compound of claim 1 wherein R9 is heteroarylalkyl and said heteroarylalkyl is pyrazolyl-(C1 to C6)alkyl-.

### Claim 5 (depends on 1)

The compound of claim 1 wherein R9 is substituted heteroarylalkyl.

### Claim 6 (depends on 1)

The compound of claim 1 wherein R9 is substituted heteroarylalkyl and said substituted heteroarylalkyl is substituted pyrazolylalkyl-.

### Claim 7 (depends on 1)

The compound of claim 1 wherein R9 is substituted heteroarylalkyl and said substituted heteroarylalkyl is selected from the group consisting of: phenyl-pyrazolyl-CH2—, N-methylpyrazolyl-CH2—, N-isopropylpyrazolyl-CH2—, N-(m-methylphenyl)-pyrazolyl-CH2—, N-(p-methylphenyl)-pyrazolyl-CH2—, N-(m-Cl-p-F-phenyl)-pyrazolyl-CH2—, N-(m-Cl-phenyl)-pyrazolyl-CH2—, N-(m-CN-phenyl)-pyrazolyl-CH2—, N-(p-CN-phenyl)-pyrazolyl-CH2—, N-(m-SO2CH3-phenyl)-pyrazolyl-CH2—, N-(p-SO2CH3-phenyl)-pyrazolyl-CH2—, N-(m,m-di-Cl-phenyl)pyrazolyl-CH2—, N-(m-F-phenyl)-pyrazolyl-CH2—, N-(m-CF3-phenyl)-pyrazolyl-CH2—, N-(quinolinyl)-pyrazolyl-CH2—, N-(pyrimidinyl)-pyrazolyl-CH2—, N-(methylquinolinyl)-pyrazolyl-CH2—, N-(m-CF3-p-F-phenyl)pyrazolyl-CH2—, N-(quinoxalinyl)-pyrazolyl-CH2—, N-(p-(CH3)SO-phenyl)-pyrazolyl-CH2—, N-(m-Br-m-CN-phenyl)-pyrazolyl-CH2—, N-(o-Cl-phenyl)pyrazolyl-CH2—, N-(o-CN-phenyl)-pyrazolyl-CH2—, N-(pyrimidinyl)-pyrazolyl-CH2—, N—(CNpyridyl)-pyrazolyl-CH2—, N-(m-F-m-CN-phenyl)-pyrazolyl-CH2—, N-(thiazolyl)-pyrazolyl-CH2—, N-(aminothiazolo[4,5-b]pyridinyl)-pyrazolyl-CH2—, N-(imidazo[1,2-a]pyridinyl)-pyrazolyl-CH2—, N-(imidazo[1,2-a]pyrimidinyl)-pyrazolyl-CH2—, N-(quinazolinyl)-pyrazolyl-CH2—, N-(3H-imidazo[4,5-b]pyridinyl)-pyrazolyl-CH2—, N-([1,5]-naphthyridinyl)-pyrazolyl-CH2—, N-(1-isopropyl-2-methyl-1H-benzoimidazolyl)-pyrazolyl-CH2—, N-(1,2-dimethyl-1H-benzoimidazolyl)-pyrazolyl-CH2—, N-(1-methyl-2-CF3-1H-benzoimidazolyl)-pyrazolyl-CH2—, N-(1-methyl-2-isopropyl-1H-benzoimidazolyl)-pyrazolyl-CH2—, N-(1-methyl-2-pyridin-3-yl-1H-benzoimidazolyl)-pyrazolyl-CH2—, N—(H2NSO2 phenyl)-pyrazolyl-CH2—, N—(CH3NHSO2phenyl)-pyrazolyl-CH2—, N-(piperazinylSO2phenyl)-pyrazolyl-CH2—, N-(p-(CH3)2NSO2)-m-Cl-phenyl)-pyrazolyl-CH2—

### Claim 8 (depends on 1)

The compound of claim 1 wherein R9 is a substituted heteroarylalkyl and said substituted heteroarylalkyl is substituted pyrazolyl-CH2—.

### Claim 9 (depends on 1)

The compound of claim 1 wherein R9 is substituted heteroarylalkyl and said substituted heteroarylalkyl is N-(methylquinolinyl)-pyrazolyl-CH2—.

### Claim 10 (depends on 1)

The compound of claim 1 wherein R3 is selected from the group consisting of:

### Claim 11 (depends on 1)

The compound of claim 1 wherein R3 is selected from the group consisting of:

### Claim 12 (depends on 1)

A pharmaceutical composition comprising an effective amount of at least one compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 13

A compound selected from the group consisting of:
Compound
102
103
105
116
117
119
127
128
129
130
131
132
133
134
135
136
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
210
213
216
219
222
228
233
234
235
236
241
244
245
246
247
248
309
and
310

### Claim 14 (depends on 13)

The compound of claim 13 selected from the group consisting of:
Compound
134
137
142
149
152
222
228
233
246
and
248

### Claim 15

A compound selected from the group consisting of:
Compound
5
7
8
13
14
47
53
64
65
71
85
86
87
92
93
99
100
101
102
103
104
105
106
107
108
113
114
115
116
117
118
119
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
171
174
175
176
177
178
179
180
181
182
183
184
185
186
200
201
202
203
205
206
207
210
213
216
219
222
228
233
234
235
238
241
244
245
246
247
248
254
255
256
257
258
309
and
310

### Claim 16 (depends on 15)

The compound of claim 15 selected from the group consisting of:
Compound
144
149
151
222
228
233
241
246
and
248

### Claim 17 (depends on 16)

The compound of claim 16 wherein said compound is compound 144:

### Claim 18 (depends on 16)

The compound of claim 16 wherein said compound is compound 149:

### Claim 19 (depends on 16)

The compound of claim 16 wherein said compound is compound 151:

### Claim 20 (depends on 16)

The compound of claim 16 wherein said compound is compound 222:

### Claim 21 (depends on 16)

The compound of claim 16 wherein said compound is compound 228:

### Claim 22 (depends on 16)

The compound of claim 16 wherein said compound is compound 233:

### Claim 23 (depends on 16)

The compound of claim 16 wherein said compound is compound 241:

### Claim 24 (depends on 16)

The compound of claim 16 wherein said compound is compound 246:

### Claim 25 (depends on 16)

The compound of claim 16 wherein said compound is compound 248:
